Sanuwave Q1 rev $9.6M (+3.1% YoY); net loss $1.4M; guides Q2 growth 10-15%

SANUWAVE Health, Inc.

2026-Q1 EPS reported -$0.17 revenue$9,619,000

Q1 revenue $9.6M, up 3.1% from $9.3M YoY; gross margin 77.3% vs 79.0%.
GAAP operating loss $1.1M, a $1.7M swing from $0.6M operating income YoY.
Ultramist consumables revenue $6.7M, up 15% YoY; set new all-time unit volume record.
Adjusted EBITDA $1.1M vs $2.3M YoY; net loss $1.4M, improved from $6.1M loss (prior year had $4.9M non-cash derivative loss).
Guides Q2 2026 revenue $11.1-11.6M (10-15% growth); reaffirms FY 2026 revenue $51-55M (16-25% growth).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

SANUWAVE Health, Inc. reported the three months ended March 31, 2026 results: revenue $9.6 million. Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $9.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025.

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-034149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.